<DOC>
	<DOCNO>NCT01204086</DOCNO>
	<brief_summary>The purpose study establish clinical effectiveness antidepressant pharmacogenomic approach , determine level inflammatory factor baseline end point study Taiwanese major depressive disorder ( MDD ) patient .</brief_summary>
	<brief_title>Pharmacogenomics Studies Antidepressants</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Age : 1665 year old Signed informed consent patient legal representative Hamilton Rating Scale Depression ( HDRS ) score â‰¥ 16 A diagnosis MDD accord DSMIV criterion make specialist psychiatry monoamine oxidase inhibitor antidepressant treatment within two week prior enter study A DSMIV diagnosis substance abuse within past three month An organic mental disease , mental retardation dementia A serious surgical condition physical illness Patients pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Antidepressants</keyword>
	<keyword>Pharmacogenetics</keyword>
	<keyword>venlafaxine</keyword>
	<keyword>fluoxetine</keyword>
</DOC>